Evidence map›Paper›PMID 42743350›Full record

ArticlePloS one2026

Exploring systemic erythropoietin in diabetic retinopathy: Longitudinal associations and biomarker potential in the LANDMark cohort.

Ingrid A Wise, Siska Dupont Berry, Alisa McKenzie, Jason C Steel, Katie Edwards, Nathan Efron, Christopher J Layton, Charmaine A Ramlogan-Steel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ingrid A WiseSchool of Health, Medical and Applied Sciences, Central Queensland University, CairnsQLD, Australia.ORCID https://orcid.org/0000-0001-6845-535X
Siska Dupont BerrySchool of Health, Medical and Applied Sciences, Central Queensland University, North Rockhampton, QLD, Australia.
Alisa McKenzieSchool of Health, Medical and Applied Sciences, Central Queensland University, North Rockhampton, QLD, Australia.
Jason C SteelSchool of Health, Medical and Applied Sciences, Central Queensland University, North Rockhampton, QLD, Australia.
Katie EdwardsCentre for Vision and Eye Research, School of Clinical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
Nathan EfronCentre for Vision and Eye Research, School of Clinical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
Christopher J LaytonCentre for Vision and Eye Research, School of Clinical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
Charmaine A Ramlogan-SteelSchool of Health, Medical and Applied Sciences, Central Queensland University, North Rockhampton, QLD, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsDiabetes mellitus (DM) is a chronic, multifactorial disease with systemic effects, demanding ongoing clinical vigilance and risk-reduction strategies. Among its most prevalent microvascular complications is diabetic retinopathy (DR), affecting 30-40% of individuals with DM and associated with sustained hyperglycaemia. This study investigates the role of erythropoietin (EPO), a glycoprotein primarily known for its role in erythropoiesis, in retinal pathology.

methodsSecondary analysis was conducted on 117 participants from the Australian cohort of the LANDMark study, examining the relationship between systemic EPO levels and DR severity, as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.

resultsSignificant positive correlations were observed between serum EPO and DR severity at both baseline and the four-year follow-up (baseline: ρ = 0.212, p = 0.025; four-year ρ = 0.205, p = 0.030). Ordinal regression indicated that both baseline and four-year EPO levels were associated with higher DR severity at the four-year follow-up (baseline: log-odds coefficient = 2.258, OR ≈ 9.57, p < 0.01; four-year: log-odds coefficient = 2.111, OR ≈ 8.26, p = 0.01).

conclusionThese findings suggest that systemic EPO shows a modest association with subsequent retinopathy severity and may reflect an exploratory biomarker of ocular disease activity.

Indexed as

Diabetic RetinopathyErythropoietinAgedAustraliaBiomarkersCohort StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedSeverity of Illness IndexBiomarkersErythropoietin

Identifiers

PMID42743350
PMCPMC13577516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.